Actively Recruiting
Study of ZG006 Safety, Tolerability, and Effectiveness in Advanced Small Cell Lung Cancer and Neuroendocrine Carcinoma with Dose Escalation and Expansion Phases
Led by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Updated on 2026-10-19
265
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety, tolerability, and effectiveness of ZG006 in people with advanced small-cell lung cancer or neuroendocrine carcinoma. This open-label, multicenter Phase III study includes two parts a Phase I dose-escalation to find safe doses and a Phase II dose-expansion to explore effectiveness and safety of ZG006 monotherapy in advanced small-cell lung cancer. The study aims to identify the best dosing based on safety, early effectiveness, and drug behavior in the body. ZG006 is given as an intravenous infusion. The dose-escalation part tests six increasing doses from 0.1 mg to 30 mg to evaluate safety and tolerability. The dose-expansion part has three cohorts, including a two-stage cohort for dose optimization and a pivotal stage for patients receiving third-line or later treatment for advanced small-cell lung cancer. Approximately 30 patients per dose group will be enrolled in the optimization stage. Participants will be monitored for up to approximately 2 to 3 years, assessing response to treatment, survival, and adverse events. Researchers will collect data on objective response rate, overall survival, duration of response, and disease control rate, while tracking any side effects. The study includes regular assessments to evaluate safety and effectiveness throughout the trial period.
CONDITIONS
Brief Title
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
Research Team
H
Hewen Yin
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here